Cargando…
Orthotopic T-Cell Receptor Replacement—An “Enabler” for TCR-Based Therapies
Natural adaptive immunity co-evolved with pathogens over millions of years, and adoptive transfer of non-engineered T cells to fight infections or cancer so far exhibits an exceptionally safe and functional therapeutic profile in clinical trials. However, the personalized nature of therapies using v...
Autores principales: | Schober, Kilian, Müller, Thomas R., Busch, Dirk H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7348731/ https://www.ncbi.nlm.nih.gov/pubmed/32492858 http://dx.doi.org/10.3390/cells9061367 |
Ejemplares similares
-
Orthotopic T-cell receptor replacement in primary human T cells using CRISPR-Cas9-mediated homology-directed repair
por: Moosmann, Carolin, et al.
Publicado: (2021) -
A T‐cell reporter platform for high‐throughput and reliable investigation of TCR function and biology
por: Müller, Thomas R, et al.
Publicado: (2020) -
Evolution of CD8(+) T Cell Receptor (TCR) Engineered Therapies for the Treatment of Cancer
por: Sun, Yimo, et al.
Publicado: (2021) -
P69. Targeting naturally presented, leukemia-derived HLA ligands with TCR-transgenic T cells for the treatment of therapy refractory leukemias
por: Richard, K, et al.
Publicado: (2014) -
Engineering Strategies to Enhance TCR-Based Adoptive T Cell Therapy
por: Rath, Jan A., et al.
Publicado: (2020)